{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["TMZ", "siPLK1", "\ufeffco-delivery", "\ufeffdrug resistance", "\ufeffglioma", "\ufeffpolymeric micelle"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32494134", "DateCompleted": {"Year": "2020", "Month": "07", "Day": "22"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "29"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "05", "Day": "12"}], "Language": ["eng"], "ELocationID": ["10.2147/IJN.S243878"], "Journal": {"ISSN": "1178-2013", "JournalIssue": {"Volume": "15", "PubDate": {"Year": "2020"}}, "Title": "International journal of nanomedicine", "ISOAbbreviation": "Int J Nanomedicine"}, "ArticleTitle": "Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.", "Pagination": {"StartPage": "3347", "EndPage": "3362", "MedlinePgn": "3347-3362"}, "Abstract": {"AbstractText": ["Temozolomide (TMZ) is the first-line chemotherapeutic option to treat glioma; however, its efficacy and clinical application are limited by its drug resistance properties. Polo-like kinase 1 (PLK1)-targeted therapy causes G2/M arrest and increases the sensitivity of glioma to TMZ. Therefore, to limit TMZ resistance in glioma, an angiopep-2 (A2)-modified polymeric micelle (A2PEC) embedded with TMZ and a small interfering RNA (siRNA) targeting <i>PLK1</i> (siPLK1) was developed (TMZ-A2PEC/siPLK).", "TMZ was encapsulated by A2-PEG-PEI-PCL (A2PEC) through the hydrophobic interaction, and siPLK1 was complexed with the TMZ-A2PEC through electrostatic interaction. Th\ufeffen, an angiopep-2 (A2) modified polymeric micelle (A2PEC) embedding TMZ and siRNA targeting polo-like kinase 1 (siPLK1) was developed (TMZ-A2PEC/siPLK).", "In vitro experiments indicated that TMZ-A2PEC/siPLK effectively enhanced the cellular uptake of TMZ and siPLK1 and resulted in significant cell apoptosis and cytotoxicity of glioma cells. In vivo experiments showed that glioma growth was inhibited, and the survival time of the animals was prolonged remarkably after TMZ-A2PEC/siPLK1 was injected via their tail vein.", "The results demonstrate that the combination of TMZ and siPLK1 in A2PEC could enhance the efficacy of TMZ in treating glioma."], "CopyrightInformation": "\u00a9 2020 Shi et al."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinical Medical College, Nanjing Medical University, Nanjing, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Second People's Hospital of Lianyungang, Lianyungang, People's Republic of China."}], "LastName": "Shi", "ForeName": "Hui", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinical Medical College, Nanjing Medical University, Nanjing, People's Republic of China."}], "LastName": "Sun", "ForeName": "Shuo", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, People's Republic of China."}], "LastName": "Xu", "ForeName": "Haoyue", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, People's Republic of China."}], "LastName": "Zhao", "ForeName": "Zongren", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, People's Republic of China."}], "LastName": "Han", "ForeName": "Zhengzhong", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, People's Republic of China."}], "LastName": "Jia", "ForeName": "Jun", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, Jiangsu, People's Republic of China."}], "LastName": "Wu", "ForeName": "Dongmei", "Initials": "D"}, {"Identifier": ["0000-0002-2801-5330"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, Jiangsu, People's Republic of China."}], "LastName": "Lu", "ForeName": "Jun", "Initials": "J"}, {"Identifier": ["0000-0002-0473-0030"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China."}], "LastName": "Liu", "ForeName": "Hongmei", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinical Medical College, Nanjing Medical University, Nanjing, People's Republic of China."}, {"Identifier": [], "Affiliation": "Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China."}], "LastName": "Yu", "ForeName": "Rutong", "Initials": "R"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Int J Nanomedicine", "NlmUniqueID": "101263847", "ISSNLinking": "1176-9114"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Cell Cycle Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Proto-Oncogene Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "RNA, Small Interfering"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Protein Serine-Threonine Kinases"}, {"RegistryNumber": "YF1K15M17Y", "NameOfSubstance": "Temozolomide"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cell Cycle Proteins"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Survival"}, {"QualifierName": [], "DescriptorName": "Drug Delivery Systems"}, {"QualifierName": ["drug effects"], "DescriptorName": "Drug Resistance, Neoplasm"}, {"QualifierName": ["drug effects"], "DescriptorName": "Endocytosis"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Endosomes"}, {"QualifierName": ["drug effects"], "DescriptorName": "G2 Phase Cell Cycle Checkpoints"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gene Silencing"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Glioma"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": [], "DescriptorName": "Mice, Nude"}, {"QualifierName": ["chemistry"], "DescriptorName": "Nanoparticles"}, {"QualifierName": ["metabolism"], "DescriptorName": "Protein Serine-Threonine Kinases"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proto-Oncogene Proteins"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "RNA, Small Interfering"}, {"QualifierName": ["administration & dosage", "pharmacology", "therapeutic use"], "DescriptorName": "Temozolomide"}, {"QualifierName": ["drug effects"], "DescriptorName": "Tissue Distribution"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}, {"QualifierName": [], "DescriptorName": "Polo-Like Kinase 1"}], "CoiStatement": "No conflicts of interest were disclosed."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2013;4:CD007415.\u00a0doi:10.1002/14651858.CD007415.pub2", "ArticleIdList": ["PMC6457743", "23633341"]}, {"Citation": "Lam FC, Morton SW, Wyckoff J, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 2018;9. doi:10.1038/s41467-018-04315-4", "ArticleIdList": ["10.1038/s41467-018-04315-4", "PMC5959860", "29777137"]}, {"Citation": "Fang C, Wang K, Stephen ZR, et al. Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Inter. 2015;7:6674\u20136682. doi:10.1021/am5092165", "ArticleIdList": ["10.1021/am5092165", "PMC4637162", "25751368"]}, {"Citation": "Bertucci A, Prasetyanto EA, Septiadi D, et al. Combined delivery of temozolomide and anti-miR221 PNA using mesoporous silica nanoparticles induces apoptosis in resistant glioma cells. Small. 2015;11:5687\u20135695. doi:10.1002/smll.201500540", "ArticleIdList": ["10.1002/smll.201500540", "26395266"]}, {"Citation": "Salazar N, Carlson JC, Huang K, et al. A chimeric antibody against ACKR3/CXCR7 in combination with TMZ activates immune responses and extends survival in mouse GBM models. Mol Ther. 2018;26:1354\u20131365. doi:10.1016/j.ymthe.2018.02.030", "ArticleIdList": ["10.1016/j.ymthe.2018.02.030", "PMC5993942", "29606504"]}, {"Citation": "Qian L, Zheng J, Wang K, et al. Cationic core-shell nanoparticles with carmustine contained within O6-benzylguanine shell for glioma therapy. Biomaterials. 2013;34:8968\u20138978. doi:10.1016/j.biomaterials.2013.07.097", "ArticleIdList": ["10.1016/j.biomaterials.2013.07.097", "23953782"]}, {"Citation": "Liang P, Shi H, Zhu W, et al. Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells. Oncotarget. 2017;8:7533.", "ArticleIdList": ["PMC5352340", "27893419"]}, {"Citation": "Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv. 2016;23(8):2720\u20132725. doi:10.3109/10717544.2015.1058434", "ArticleIdList": ["10.3109/10717544.2015.1058434", "26203691"]}, {"Citation": "Messaoudi K, Saulnier P, Boesen K, Benoit JP, Lagarce F. Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide. Int J Nanomedicine. 2014;9:1479\u20131490. doi:10.2147/IJN.S59134", "ArticleIdList": ["10.2147/IJN.S59134", "PMC3969342", "24711698"]}, {"Citation": "Xu X, Wang Z, Liu N, et al. Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ. Int J Oncol. 2018;53:189\u2013202. doi:10.3892/ijo.2018.4382", "ArticleIdList": ["10.3892/ijo.2018.4382", "29749469"]}, {"Citation": "Cheng D, Cao N, Chen J, Yu X, Shuai X. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. Biomaterials. 2012;33:1170\u20131179. doi:10.1016/j.biomaterials.2011.10.057", "ArticleIdList": ["10.1016/j.biomaterials.2011.10.057", "22061491"]}, {"Citation": "Clemente N, Ferrara B, Gigliotti C, et al. Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies. Int J Mol Sci. 2018;19:255. doi:10.3390/ijms19020255", "ArticleIdList": ["10.3390/ijms19020255", "PMC5855544", "29364157"]}, {"Citation": "Kim SS, Harford JB, Moghe M, Rait A, Pirollo KF, Chang EH. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res. 2018;46:1424\u20131440. doi:10.1093/nar/gkx1221", "ArticleIdList": ["10.1093/nar/gkx1221", "PMC5815062", "29202181"]}, {"Citation": "Pan H, Wang H, Jia Y, et al. VPA and MEL induce apoptosis by inhibiting the Nrf2-ARE signaling pathway in TMZ-resistant U251 cells. Mol Med Rep. 2017;16:908\u2013914. doi:10.3892/mmr.2017.6621", "ArticleIdList": ["10.3892/mmr.2017.6621", "28560379"]}, {"Citation": "Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2001;2:552\u2013560. doi:10.1016/S1470-2045(01)00489-2", "ArticleIdList": ["10.1016/S1470-2045(01)00489-2", "11905710"]}, {"Citation": "Li K, Liang N, Yang H, Liu H, Li S. Temozolomide encapsulated and folic acid decorated chitosan nanoparticles for lung tumor targeting: improving therapeutic efficacy both in vitro and in vivo. Oncotarget. 2017;8. doi:10.18632/oncotarget.22791", "ArticleIdList": ["10.18632/oncotarget.22791", "PMC5762324", "29340056"]}, {"Citation": "Yoo B, Ifediba MA, Ghosh S, Medarova Z, Moore A. Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ. Mol Imaging Biol. 2014;16:680\u2013689. doi:10.1007/s11307-014-0734-3", "ArticleIdList": ["10.1007/s11307-014-0734-3", "24696184"]}, {"Citation": "Gutteridge REA, Ndiaye MA, Liu X, Ahmad N. Plk1 inhibitors in cancer therapy: from laboratory to clinics. Mol Cancer Ther. 2016;15:1427\u20131435. doi:10.1158/1535-7163.MCT-15-0897", "ArticleIdList": ["10.1158/1535-7163.MCT-15-0897", "PMC4936921", "27330107"]}, {"Citation": "Strebhardt K, Ullrich A. Targeting Polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006;6:321\u2013330. doi:10.1038/nrc1841", "ArticleIdList": ["10.1038/nrc1841", "16557283"]}, {"Citation": "Jiang R, Lu X, Yang M, Deng W, Fan Q, Huang W. Monodispersed brush-like conjugated polyelectrolyte nanoparticles with efficient and visualized siRNA delivery for gene silencing. Biomacromolecules. 2013;14:3643\u20133652. doi:10.1021/bm401000x", "ArticleIdList": ["10.1021/bm401000x", "24040909"]}, {"Citation": "Jeong SB, Im JH, Yoon J, et al. Essential role of Polo-like kinase 1 (Plk1) oncogene in tumor growth and metastasis of tamoxifen-resistant breast cancer. Mol Cancer Ther. 2018;17:825\u2013837. doi:10.1158/1535-7163.MCT-17-0545", "ArticleIdList": ["10.1158/1535-7163.MCT-17-0545", "29437878"]}, {"Citation": "Czaplinski S, Hugle M, Stiehl V, Fulda S. Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis. Oncotarget. 2016;7:8700. doi:10.18632/oncotarget.3901", "ArticleIdList": ["10.18632/oncotarget.3901", "PMC4890998", "26046302"]}, {"Citation": "Pezuk JA, Brassesco MS, Morales AG, et al. Inhibition of Polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation. Cancer Biother Radio. 2013;28:516\u2013522.", "ArticleIdList": ["0"]}, {"Citation": "Sakurai Y, Hatakeyama H, Akita H, Harashima H. Improvement of doxorubicin efficacy using liposomal anti-Polo-like kinase 1 siRNA in human renal cell carcinomas. Mol Pharmaceut. 2014;11:2713\u20132719. doi:10.1021/mp500245z", "ArticleIdList": ["10.1021/mp500245z", "24800640"]}, {"Citation": "Gleixner KV, Ferenc V, Peter B, et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res. 2010;70:1513\u20131523. doi:10.1158/0008-5472.CAN-09-2181", "ArticleIdList": ["10.1158/0008-5472.CAN-09-2181", "20145140"]}, {"Citation": "Benoit DSW, Henry SM, Shubin AD, Hoffman AS, Stayton PS. pH-Responsive polymeric siRNA carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of Polo-like kinase 1. Mol Pharmaceut. 2010;7:442\u2013455. doi:10.1021/mp9002255", "ArticleIdList": ["10.1021/mp9002255", "PMC2920053", "20073508"]}, {"Citation": "Koncar RF, Chu Z, Romick-Rosendale LE, et al. PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. Oncotarget. 2017;8:15827\u201315837. doi:10.18632/oncotarget.15015", "ArticleIdList": ["10.18632/oncotarget.15015", "PMC5362526", "28178660"]}, {"Citation": "Liu NJ, Hu GZ, Wang H, Li ZH, Guo ZG. PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells. J Cell Mol Med. 2018;22:5300\u20135310. doi:10.1111/jcmm.13793", "ArticleIdList": ["10.1111/jcmm.13793", "PMC6201353", "30133120"]}, {"Citation": "Wang Y, Singh R, Wang L, et al. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget. 2016;7:47998\u201348010. doi:10.18632/oncotarget.10332", "ArticleIdList": ["10.18632/oncotarget.10332", "PMC5216995", "27384992"]}, {"Citation": "Liao G, Wang R, Rezey AC, Gerlach BD, Tang DD. MicroRNA miR-509 regulates ERK1/2, the vimentin network, and focal adhesions by targeting Plk1. Sci Rep. 2018;8:12635. doi:10.1038/s41598-018-30895-8", "ArticleIdList": ["10.1038/s41598-018-30895-8", "PMC6105636", "30135525"]}, {"Citation": "Lerner RG, Grossauer S, Kadkhodaei B, et al. Targeting a Plk1-controlled polarity checkpoint in therapy-resistant glioblastoma-propagating cells. Cancer Res. 2015;75:5355\u20135366. doi:10.1158/0008-5472.CAN-14-3689", "ArticleIdList": ["10.1158/0008-5472.CAN-14-3689", "PMC4698003", "26573800"]}, {"Citation": "Liu DZ, Cheng Y, Cai RQ, et al. The enhancement of siPLK1 penetration across BBB and its anti glioblastoma activity in vivo by magnet and transferrin co-modified nanoparticle. Nanomedicine-Uk. 2018;14:991\u20131003. doi:10.1016/j.nano.2018.01.004", "ArticleIdList": ["10.1016/j.nano.2018.01.004", "29339188"]}, {"Citation": "Jiang Y, Tang R, Duncan B, et al. Direct cytosolic delivery of siRNA using nanoparticle-stabilized nanocapsules. Angew Chem Int Ed Engl. 2015;54:506\u2013510. doi:10.1002/anie.201409161", "ArticleIdList": ["10.1002/anie.201409161", "PMC4314441", "25393227"]}, {"Citation": "Li Y, Liu R, Yang J, Ma G, Zhang Z, Zhang X. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy. Biomaterials. 2014;35:9731\u20139745. doi:10.1016/j.biomaterials.2014.08.022", "ArticleIdList": ["10.1016/j.biomaterials.2014.08.022", "25189519"]}, {"Citation": "Garber K. Alnylam launches era of RNAi drugs. Nat Biotechnol. 2018;36:777\u2013778. doi:10.1038/nbt0918-777", "ArticleIdList": ["10.1038/nbt0918-777", "30188543"]}, {"Citation": "Liu HM, Zhang YF, Xie YD, et al. Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy. Int J Nanomedicine. 2017;12:1065\u20131083. doi:10.2147/IJN.S125286", "ArticleIdList": ["10.2147/IJN.S125286", "PMC5308568", "28223799"]}, {"Citation": "Chen YC, Chinang CF, Chen LF, Liang PC, Hsieh WY, Lin WL. Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system. Biomaterials. 2014;35:4066\u20134081. doi:10.1016/j.biomaterials.2014.01.042", "ArticleIdList": ["10.1016/j.biomaterials.2014.01.042", "24513319"]}, {"Citation": "Patyka M, Sharifi Z, Petrecca K, Mansure J, Jean-Claude B, Sabri S. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status. Oncotarget. 2016;7:60245\u201360269. doi:10.18632/oncotarget.11197", "ArticleIdList": ["10.18632/oncotarget.11197", "PMC5312382", "27533246"]}, {"Citation": "Peng Y, Huang J, Xiao H, Wu T, Shuai X. Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment. <![CDATA[International Journal of Nanomedicine]]>. 2018;13:3467\u20133480. doi:10.2147/IJN.S164611", "ArticleIdList": ["10.2147/IJN.S164611", "PMC6007389", "29942129"]}, {"Citation": "Liu H, Li Y, Mozhi A, et al. SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment. Biomaterials. 2014;35:6519\u20136533. doi:10.1016/j.biomaterials.2014.04.033", "ArticleIdList": ["10.1016/j.biomaterials.2014.04.033", "24797882"]}, {"Citation": "Ozdemir-Kaynak E, Qutub AA, Yesil-Celiktas O. Advances in glioblastoma multiforme treatment: new models for nanoparticle therapy. Front Physiol. 2018;9:170. doi:10.3389/fphys.2018.00170", "ArticleIdList": ["10.3389/fphys.2018.00170", "PMC5868458", "29615917"]}, {"Citation": "Roger M, Clavreul A, Venier-Julienne M, Passirani C, Montero-Menei C, Menei P. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials. 2011;32:2106\u20132116. doi:10.1016/j.biomaterials.2010.11.056", "ArticleIdList": ["10.1016/j.biomaterials.2010.11.056", "21183214"]}, {"Citation": "Petovari G, Hujber Z, Krencz I, et al. Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells. Cancer Cell Int. 2018;18:211. doi:10.1186/s12935-018-0710-0", "ArticleIdList": ["10.1186/s12935-018-0710-0", "PMC6300020", "30574020"]}, {"Citation": "Creixell M, Peppas NA. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today. 2012;7:367\u2013379. doi:10.1016/j.nantod.2012.06.013", "ArticleIdList": ["10.1016/j.nantod.2012.06.013", "PMC4527553", "26257819"]}, {"Citation": "Fan Y, Xue W, Schachner M, Zhao W.,Honokiol eliminates glioma/glioblastoma stem cell-like cells via JAK-STAT3 signaling and inhibits tumor progression by targeting epidermal growth factor receptor. Cancers (Basel). 2018;11. doi:10.3390/cancers11010022", "ArticleIdList": ["10.3390/cancers11010022", "PMC6356849", "30587839"]}, {"Citation": "Parajuli P, Mittal S. Picture of glioma stem cells has become a Notch brighter. Stem Cell Investig. 2018;5:42. doi:10.21037/sci.2018.11.02", "ArticleIdList": ["10.21037/sci.2018.11.02", "PMC6286897", "30596082"]}, {"Citation": "Zhi T, Jiang K, Xu X, et al. ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1. Neuro Oncol. 2019;21:462\u2013473. doi:10.1093/neuonc/noy207", "ArticleIdList": ["10.1093/neuonc/noy207", "PMC6422441", "30590814"]}, {"Citation": "Zhang C, Yang X, Fu C, Liu X. Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/beta-catenin signaling pathway. Gene. 2018;672:172\u2013179. doi:10.1016/j.gene.2018.06.030", "ArticleIdList": ["10.1016/j.gene.2018.06.030", "29906532"]}, {"Citation": "Wu Q, Cao Z, Xiao W, et al. Study on therapeutic action and mechanism of TMZ combined with RITA against glioblastoma. Cell Physiol Biochem. 2018;51:2536\u20132546. doi:10.1159/000495923", "ArticleIdList": ["10.1159/000495923", "30562758"]}, {"Citation": "Wang Y, Wu L, Yao Y, Lu G, Xu L, Zhou J. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. Cancer Lett. 2018;436:1\u20139. doi:10.1016/j.canlet.2018.08.007", "ArticleIdList": ["10.1016/j.canlet.2018.08.007", "30118839"]}, {"Citation": "Yang B, Ma YB, Chu SH. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells. Cancer Gene Ther. 2018;25:309\u2013316. doi:10.1038/s41417-018-0040-3", "ArticleIdList": ["10.1038/s41417-018-0040-3", "30140041"]}]}], "History": [{"Year": "2019", "Month": "12", "Day": "27"}, {"Year": "2020", "Month": "4", "Day": "15"}, {"Year": "2020", "Month": "6", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "6", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "5", "Day": "12"}], "PublicationStatus": "epublish", "ArticleIdList": ["32494134", "PMC7229804", "10.2147/IJN.S243878", "243878"]}}]}